Dutasteride
Dual inhibitor of both type I and type II 5-alpha reductase isoenzymes, reducing serum DHT by over 90%. The 5-week terminal half-life reflects extensive tissue binding and enterohepatic recirculation. More complete DHT suppression than finasteride but with correspondingly greater neurosteroid disruption.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- total-testosterone
- free-testosterone
- dhea-s
- estradiol
- psa
- alt
- ast
- pregnancy-exposure
- hepatic-impairment
- pediatric-use
- PMID:17032385Dutasteride, a dual 5alpha-reductase inhibitor, for the treatment of benign prostatic hyperplasia — Expert Opin Pharmacother, 2006
- PMID:16728986The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss — J Am Acad Dermatol, 2006
Dutasteride is the nuclear option in the 5-alpha reductase category. 90%+ DHT suppression versus finasteride 70%. Dual isoenzyme inhibition versus single. And a 5-week half-life that means once you take it, you are committed for months. There is no rapid washout. This molecule was designed for prostate volume reduction where maximum DHT suppression is the explicit goal. Using it for hair loss is a risk-benefit calculation that most practitioners get wrong by focusing exclusively on efficacy without weighting the neurosteroid consequences of near-total DHT elimination.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See Dutasteride in a protocol matched to you